Abstract
Major depressive disorder has been associated with a significant risk for the development and progression of cardiovascular disease. The impact of depression on cardiovascular morbidity and mortality is sex-dependent, with women having a greater risk for this comorbidity and poorer clinical outcomes. Although management of depressive symptomatology has been associated with a better prognosis in patients with comorbid depression and cardiovascular disease, a significant proportion remained undertreated, are refractory to antidepressant medications, or present cardiovascular side effects and drug interactions. The development and validation of novel, nonpharmacological interventions targeting the comorbidity of depression and cardiovascular disease in a sex-dependent manner may have a significant impact on the improvement of depressive symptomatology and cardiovascular outcomes with a better safety profile and broader applicability. The aim of this review is to evaluate existing nonpharmacologic therapeutics used for the management of this comorbidity and to review emerging interventions with potential sex-dependent effects on this population. [ Psychiatr Ann . 2022;52(1):14–19.]
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
